Brca2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | BRCA2 Protein |
| Gene | BRCA2 |
| UniProt ID | P51587 |
| PDB IDs | 1MIU, 1N5W, 2JDD |
| Molecular Weight | 384 kDa |
| Subcellular Localization | Nucleus, Cytoplasm |
| Protein Family | Tumor Suppressor |
BRCA2 is a nuclear protein that plays a critical role in homologous recombination (HR) repair of DNA double-strand breaks. The protein has an N-terminal transactivation domain and eight BRC repeats that mediate RAD51 binding. The C-terminal domain is essential for loading RAD51 onto single-stranded DNA. BRCA2 is essential for genome stability and tumor suppression.
The BRCA2 Protein (BRCA2) has the following structural features:
Available PDB structures: 1MIU, 1N5W, 2JDD
BRCA2 plays critical roles in:
BRCA2 dysfunction contributes to:
| Disease | Mechanism |
|---|---|
| Alzheimer's Disease | BRCA2 mutations/dysfunction |
| Parkinson's Disease | BRCA2 mutations/dysfunction |
| Amyotrophic Lateral Sclerosis | BRCA2 mutations/dysfunction |
| Breast Cancer | BRCA2 mutations/dysfunction |
| Ovarian Cancer | BRCA2 mutations/dysfunction |
BRCA2 is being explored as a therapeutic target:
| Strategy | Agent | Development Stage |
|---|---|---|
| Gene therapy | AAV-based delivery | Preclinical |
| Small molecules | DNA repair enhancers | Research |
| Combination therapy | PARP inhibitors | Clinical (cancer) |
The study of Brca2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Current research on BRCA2 in neurodegeneration:
BRCA2 knockout mice show: